XTalks

DECEMBER 13, 2023

Modern is making significant strides in advancing its mRNA technology and diversifying its product portfolio to address a broad spectrum of medical conditions. Dynavax boasts two successful commercial products in its portfolio. Notably, R&D expenditures for the second quarter of 2023 surged by 62 percent to reach $1.1

Genetics 111

Genetics Vaccination Vaccine DNA 111

Drug Discovery World

NOVEMBER 15, 2022

Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

JULY 26, 2023

This leap in understanding, which has been facilitated by the emergence of next generation sequencing (NGS) technologies and bioinformatics tools such as artificial intelligence (AI), has brought forward a new wave of precision medicine resources, diagnostics, and therapeutics specifically aiming to leverage the microbiome.

Medicine 52

Medicine Genome Genomics Bioinformatics 52

Drug Discovery World

NOVEMBER 9, 2023

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, on: ‘Accelerating early discovery through htp and high-speed antibody production’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

SEPTEMBER 7, 2022

By Ashoka Rajendra , Head of Development & Manufacturing Products at Benchling. Many companies have embarked on a digitalisation journey, convinced that their notebook entries, DNA and protein designs, samples used in experiments, and experimental conditions should all be tracked and stored in software.

Scientist 52

Scientist Life Science Antibody Protein 52

Drug Discovery World

NOVEMBER 30, 2023

Next-generation immunotherapies In the session focused on cell-based immunotherapies, Steven Quistad, Senior Applications Scientist, DNA Script, presented on how to rapidly assemble genes in a laboratory using automated enzymatic oligo synthesis. To demonstrate the utility of the company’s SYNTAX system in gene assembly, the 1.7

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

NOVEMBER 13, 2023

Novel/alternative ML-enabled screening technologies for higher POS Following chairperson’s remarks from M Frank Erasmus, PhD, Head, Bioinformatics, Specifica, there will be four presentations and a panel discussion. Jens Frauenfeld, PhD, Founder, CEO, Salipro Biotech, on: ‘Structure-function studies of salipro-CXCRs for antibody development’.

Protein 59

Protein Antibody Engineer Scientist 59

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genome 52

Genome Genomics RNA Genome Project 52

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. Moving on From the Amyloid Hypothesis. “I And then, always, ‘science matters.’

Vaccination 52

Vaccination Vaccine Regulation Drugs 52